Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal De La Societe De Biologie|October 17, 2009
[The discovery process in the pharmaceutical industry]Bernard Scatton
Biologie Aujourd'Hui|April 20, 2011
[Physiopathology and genetics of epilepsy: recent data]Jean-Marie Stutzmann, Bernard Scatton
Biological Psychiatry|February 5, 2005
Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodentsGuy Griebel, Jeanne Stemmelin, Bernard Scatton
Molecular Pharmacology|November 12, 2005
The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytesMagali Gary-Bobo, Ghizlane Elachouri, Bernard Scatton, et al.
The European Journal of Neuroscience|December 7, 2007
CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamusFrédéric Béquet, Françoise Uzabiaga, Mathieu Desbazeille, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 18, 2002
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disordersGuy Griebel, Jacques Simiand, Claudine Serradeil-Le Gal, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 7, 2003
SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activityRonan Depoortere, Denis Boulay, Ghislaine Perrault, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 22, 2002
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disordersGuy Griebel, Jacques Simiand, Régis Steinberg, et al.
CNS Drug Reviews|February 22, 2003
SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasmsGuy Griebel, Ghislaine Perrault, Jacques Simiand, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 29, 2006
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophreniaPhilippe Pichat, Olivier E Bergis, Jean-Paul Terranova, et al.
Pageof 3